A high dose of Novo Nordisk’s obesity drug Wegovy led patients to lose substantial weight in a clinical trial, but still less ...

The US Food and Drug Administration (FDA) has approved the first prescription medicine for adults with moderate-to-severe obstructive sleep apnea (OSA): the weight-loss drug Zepbound. Zepbound may ...

Study participants were randomly assigned 1:1 to receive Zepbound (10mg or 15mg; maximum tolerated dose) or placebo injected subcutaneously once weekly. The primary endpoint was the change from ...

They received the maximum tolerated dose of Zepbound (10 mg or 15 mg) or Wegovy (1.7 mg or 2.4 mg) for 72 weeks. (No participant had diabetes; Lilly markets tirzepatide as Mounjaro to people with ...

The Food and Drug Administration approved Eli Lilly's blockbuster weight loss drug Zepbound for treating patients with the most common sleep-related breathing disorder. The weekly injection is now ...

Eli Lilly said the Food and Drug Administration approved Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity. The company said Zepbound, or tirzepatide, is the first and ...

The Food and Drug Administration approved Eli Lilly’s weight-loss drug Zepbound on Dec. 27 to treat sleep apnea, a common but potentially serious sleep-related breathing disorder, making it the ...

Zepbound (tirzepatide), manufactured by Fortune 500 firm Eli Lilly & Co., bested competitor Wegovy (semaglutide), a product of Global 500 company Novo Nordisk, in a 2023–24 randomized clinical ...

(CNN) — The US Food and Drug Administration on Friday approved the first prescription medicine for obstructive sleep apnea: the weight-loss drug Zepbound. (CNN) — The US Food and Drug ...